TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03265119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEVI-001
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
Study: NCT03868176

Intervention type: OTHER
Intervention: short message service
Description: short message service
Study: NCT04372810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude manipulation (HVLA)
Description: The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care assessment and guidance
Description: Evaluation and care guidelines on glycemic control and diabetic foot care.
Study: NCT03989297

Intervention type: RADIATION
Intervention: Radiation
Description: Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
Study: NCT03228134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ke Chuan Liu Wei Granule
Description: Traditional Chinese Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang He Ping Chuan Granule
Description: Traditional Chinese Medicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ke Chuan Liu Wei Granule placebo
Description: Placebo

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Yang He Ping Chuan Granule placebo
Description: Placebo
Study: NCT06316414

Intervention type: BIOLOGICAL
Intervention: Omalizumab
Description: Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
Study: NCT03056131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
Study: NCT02516124

Intervention type: PROCEDURE
Intervention: Autologous HSCT
Description: 1st AHSCT
Study: NCT04372810

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Care assessment and guidance
Description: Evaluation and care guidelines on glycemic control and diabetic foot care.
Study: NCT00795379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: Exposure to internal stimuli.
Study: NCT03057145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
Study: NCT03265093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin Injection
Description: Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid injection
Study: NCT01067339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, by mouth, once daily for six months
Study: NCT03183739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 will be administered orally.
Study: NCT02263638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
Study: NCT02097134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IA
Study: NCT03183739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT04041869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapTrek
Description: Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
Study: NCT03833076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device Procto
Description: Medical device Procto presents itself as a translucent green gel with a typical smell.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: IP placebo presents itself as a translucent green gel with a typical smell.
Study: NCT04945980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
Study: NCT00405574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-224
Description: ATN-224 high dose: 300mg ATN-224 low dose: 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-224
Description: ATN-224 high dose: 300mg ATN-224 low dose: 30mg
Study: NCT01985984

Intervention type: RADIATION
Intervention: Radiation alone
Description: Radiation alone

Intervention type: RADIATION
Intervention: Radiation in combination with systemic therapy
Description: Radiation in combination with systemic therapy
Study: NCT00660855

Intervention type: DRUG
Group type: OTHER
Intervention: parecoxib/valdecoxib
Description: parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
Study: NCT02338947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump coronary-artery bypass grafting
Description: Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-pump coronary-artery bypass grafting
Description: Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
Study: NCT03262948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
Study: NCT02059928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous Device
Study: NCT03824197

Intervention type: OTHER
Group type: OTHER
Intervention: EVOO
Description: Extra-virgin olive oil that is rich with oleocanthal and other phenols.

Intervention type: OTHER
Group type: OTHER
Intervention: OO
Description: Olive oil low in oleocanthal and other phenols.
Study: NCT01101841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brisdelle (paroxetine mesylate)
Description: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Study: NCT01438827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanz Phleum pratense
Description: Suspension for Injection, Every 6 weeks for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanz Phleum pratense
Description: Suspension for Injection, Every 6 weeks for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for Injection, Every 6 weeks for one year
Study: NCT03100786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
Study: NCT00935415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules of matching placebo
Study: NCT04143477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: Oral
Study: NCT01101841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Study: NCT03552159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Activity scheduling, monitoring, review and re-scheduling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Education on dementia, caregiving stress, event scheduling and communication skills

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Education on dementia, caregiving stress, event scheduling and communication skills
Study: NCT05518279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Pill
Description: Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
Study: NCT00727194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
Study: NCT03635970

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: celular therapy
Description: application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: celular therapy
Description: application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
Study: NCT03660059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peficitinib
Description: Oral
Study: NCT00727194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV weekly for 4 doses then every two weeks for 7 doses
Study: NCT03225794

Intervention type: DIAGNOSTIC_TEST
Intervention: Simian foamy virus Infection
Description: Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
Study: NCT03660059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plaebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.
Study: NCT02708940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participatory technology development
Description: Creating mobile support tools by patients and their therapists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as part of the UCLA PHP and IOP programs
Study: NCT00845377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial support for depressed elderly
Description: The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
Study: NCT01516190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise sessions and independent exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgical preparation program
Description: Book, tapes, CD
Study: NCT03935035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-delivered Cognitive Therapy for PTSD (iCT)
Description: Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
Study: NCT01356511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone, po, 1 mg/kg/d, for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, po, 40 mg/d, for 4 days.
Study: NCT04621227

Intervention type: DRUG
Group type: OTHER
Intervention: PF-06882961
Description: 120 mg and 200 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: 2mg single dose
Study: NCT03981315

Intervention type: DIAGNOSTIC_TEST
Intervention: Bile test
Description: Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
Study: NCT02694081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y Reconstruction
Description: All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
Study: NCT00837148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Dacarbazine
Description: Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance.
Study: NCT02906670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
Study: NCT02694081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth II Reconstruction
Description: All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
Study: NCT01433263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338 active drug
Study: NCT03981315

Intervention type: DIAGNOSTIC_TEST
Intervention: Bile test
Description: Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Bile test
Description: Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
Study: NCT01433263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BYM338 active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01589822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL Fibrin Sealant
Description: Intraoperative

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL Fibrin Sealant
Description: Intraoperative